Inspire Corporate Bond ETF(IBD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IBD Inspire Corporate Bond ETF

交易中 04-07 13:21:07 EDT

23.83

+0.00

+0.00%

最高23.83	最低23.76	成交量2.66万
今开23.82	昨收23.83	日振幅0.31%
总市值4.84亿	流通市值4.69亿	总股本2,030万
成交额63.38万	换手率0.14%	流通股本1,970万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.8296,"timestamp":1775582008562,"preClose":23.83,"halted":0,"volume":26626,"delay":0,"changeRate":-0.000016785564414564324,"floatShares":19700000,"shares":20300000,"eps":0,"marketStatus":"交易中","change":-0.0004,"latestTime":"04-07 13:21:07 EDT","open":23.8215,"high":23.83,"low":23.755,"amount":633783.630436,"amplitude":0.003147,"askPrice":23.83,"askSize":200,"bidPrice":23.61,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1775592000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.83,"sharesOutstanding":19800000,"nav":23.83,"aum":483798823.49,"dividendRate":0.042678,"bidAskSpread":0.002607,"postHourTrading":{"tag":"盘后","latestPrice":23.83,"preClose":23.83,"latestTime":"19:34 EDT","volume":12,"amount":286.62,"timestamp":1775518490374,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.171234},"requestUrl":"/m/hq/s/IBD/wiki","defaultTab":"wiki","newsList":[{"id":"2614049751","title":"Vivosim Labs, Inc.盘中异动 急速上涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614049751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614049751?lang=zh_cn&edition=full","pubTime":"2026-02-26 04:11","pubTimestamp":1772050297,"startTime":"0","endTime":"0","summary":"北京时间2026年02月26日04时11分，Vivosim Labs, Inc.股票出现异动，股价快速上涨5.41%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226041137a4c85b45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226041137a4c85b45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VIVS","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613717630","title":"中国抗体-B(03681)：SM17用于治疗IBD的IND获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613717630?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:01","pubTimestamp":1771941713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 公布，于2026年2月24日，公司同类首创治疗产品SM17用于治疗炎症性肠病患者的新药临床试验申请已获中国国家药品监督管理局批准。公司已完成针对使用SM17皮下注射剂型的健康志愿者I期桥接实验的随访。该机制使SM17成为UC有前景的治疗候选药物，其中已证实IL-25发挥促炎作用。公司进一步认为，靶向2型炎性通路上游调控因子的治疗策略可支持SM17成为用于治疗AD及IBD的具差异化、安全性更佳且有效的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1161","IBD","IND","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609432256","title":"释放pipeline in a drug潜力 NLRP3能否催生下一个“药王”?","url":"https://stock-news.laohu8.com/highlight/detail?id=2609432256","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609432256?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:35","pubTimestamp":1770280559,"startTime":"0","endTime":"0","summary":"近期，英硅智能(03696)宣布提名靶向NLRP3的外周限制性抑制剂ISM5059，该候选药物具有新颖母核，由英硅智能自有Pharma.AI平台驱动设计。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260205/20260205163220_51027.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260205/20260205163220_51027.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["PD","BK4135","BBB","IBD","LU1169589451.USD","BK4023","LU1169590202.USD","BK4132","AD","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602122803","title":"Vivosim Labs, Inc.盘中异动 大幅下跌8.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602122803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602122803?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:55","pubTimestamp":1767894943,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日01时55分，Vivosim Labs, Inc.股票出现异动，股价大幅下挫8.35%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.93%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109015545a4acf44f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109015545a4acf44f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VIVS","BK4139","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590550876","title":"中信证券：新老管线数据读出频现 MNC加速IBD领域布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590550876","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590550876?lang=zh_cn&edition=full","pubTime":"2025-12-11 09:34","pubTimestamp":1765416866,"startTime":"0","endTime":"0","summary":"MNC加速IBD领域布局，中国创新药企业在差异化赛道崭露头角。MNC加速IBD领域布局，中国创新药企业在差异化赛道崭露头角作为自身免疫疾病领域中，患者人数众多且当前一年维持期疗效仍仅有30%-50%临床缓解率的适应症，IBD吸引了众多MNC布局。根据过往交易规模以及MNC对产品峰值的预期，该行预计一项临床阶段的优质IBD资产的交易对价在20亿美金以上。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","BK1147","BK0183","LU0405327494.USD","BK0188","LU1255011170.USD","IBD","BK0196","LU1997245177.USD","LU1997245094.SGD","LU1997244956.HKD","LU1328615791.USD","LU2289578879.USD","BK0012","LU1794554557.SGD","LU1720050803.USD","LU1064130708.USD","LU2495084118.USD","BK1521","BK1564","LU0405327148.USD","BK0276","BK1516","LU2148510915.USD","600030","BK0028","LU1655091616.SGD","06030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2587075284","title":"Vivosim Labs, Inc.盘中异动 早盘股价大涨7.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2587075284","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587075284?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:33","pubTimestamp":1764340392,"startTime":"0","endTime":"0","summary":"北京时间2025年11月28日22时33分，Vivosim Labs, Inc.股票出现波动，股价大幅上涨7.31%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.19%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128223312a4c0a7f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128223312a4c0a7f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VIVS","IBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518420501","title":"Organovo Holdings, Inc.盘中异动 下午盘快速下跌6.37%报0.422美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518420501","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518420501?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:05","pubTimestamp":1741626341,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时05分，Organovo Holdings, Inc.股票出现异动，股价大幅下挫6.37%。截至发稿，该股报0.422美元/股，成交量27.3231万股，换手率1.57%，振幅8.70%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311010542abf34a26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311010542abf34a26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBD","ONVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517908945","title":"Organovo Holdings, Inc.盘中异动 快速下挫6.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517908945?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:43","pubTimestamp":1741185821,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时43分，Organovo Holdings, Inc.股票出现波动，股价急速下挫6.10%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224341963adf65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224341963adf65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516260096","title":"艾伯维杀入减重赛道 寻找下一个“药王”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2516260096","media":"新京报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516260096?lang=zh_cn&edition=full","pubTime":"2025-03-04 18:00","pubTimestamp":1741082458,"startTime":"0","endTime":"0","summary":"艾伯维还是杀入了减重赛道。美国时间3月3日，艾伯维宣布与Gubra公司达成许可协议，共同开发用于治疗肥胖症的潜在同类最佳长效胰淀素类似物，交易总额最高可达22亿美元。当前减重赛道火热，2024年两款全球畅销减重药物更是合计卖出了457.42亿美元。自旗下修美乐因专利到期等因素销售开始下滑后，艾伯维业绩受到影响，近年来也在频频对外合作，提振业绩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043336126264.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043336126264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634704","title":"Organovo Holdings, Inc.股价重挫10.77% 市值跌109.04万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516634704?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:30","pubTimestamp":1741012250,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时30分，Organovo Holdings, Inc.股票出现异动，股价大幅下跌10.77%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032230509637ab9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032230509637ab9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514583373","title":"Organovo Holdings, Inc.盘中异动 早盘大幅跳水5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514583373","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514583373?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:51","pubTimestamp":1740754266,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时51分，Organovo Holdings, Inc.股票出现异动，股价急速下挫5.55%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.22%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822510696341eaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822510696341eaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514385603","title":"Organovo Holdings, Inc.盘中异动 早盘股价大跌8.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385603?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:37","pubTimestamp":1740667027,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时37分，Organovo Holdings, Inc.股票出现波动，股价急速下挫8.09%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.85%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272237079632b21c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272237079632b21c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514518578","title":"Organovo Holdings, Inc.股价拉升11.82% 市值涨292.98万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514518578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514518578?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:32","pubTimestamp":1740580349,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时32分，Organovo Holdings, Inc.股票出现异动，股价快速拉升11.82%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Enveric Biosciences, Inc.、Nutriband Inc C/Wts 、Channel Therapeutics Corporation涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2837.58%、119.45%、90.45%，振幅较大的相关个股有Enveric Biosciences, Inc.、Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.，振幅分别为35.59%、16.86%、14.35%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223230a254f6af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223230a254f6af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514090481","title":"Organovo Holdings, Inc.股价上涨238.75% 市值涨5209.05万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090481","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514090481?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:31","pubTimestamp":1740493865,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分，Organovo Holdings, Inc.股票出现异动，股价急速上涨238.75%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Organovo Holdings, Inc.、Moleculin Biotech, Inc.、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为746.23%、508.78%、459.72%，振幅较大的相关个股有Organovo Holdings, Inc.、Igm Biosciences, Inc.、Bicara Therapeutics Inc.，振幅分别为8.13%、7.46%、5.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223105abdc7da6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223105abdc7da6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514670511","title":"Organovo Holdings, Inc.盘中异动 股价大跌5.15%报0.350美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514670511","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514670511?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:35","pubTimestamp":1740429350,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时35分，Organovo Holdings, Inc.股票出现波动，股价快速跳水5.15%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225043550962ee007&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225043550962ee007&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512480684","title":"Organovo Holdings, Inc.盘中异动 股价大跌5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512480684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512480684?lang=zh_cn&edition=full","pubTime":"2025-02-20 01:31","pubTimestamp":1739986261,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日01时31分，Organovo Holdings, Inc.股票出现波动，股价快速下跌5.51%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013101988b4e5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013101988b4e5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512612521","title":"Organovo Holdings, Inc.盘中异动 股价大跌5.96%报0.363美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512612521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512612521?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:25","pubTimestamp":1739892328,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时25分，Organovo Holdings, Inc.股票出现波动，股价大幅下挫5.96%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232528a24ab8fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232528a24ab8fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONVO","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511137666","title":"Organovo Holdings, Inc.盘中异动 股价大涨5.82%报0.400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511137666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511137666?lang=zh_cn&edition=full","pubTime":"2025-02-15 02:04","pubTimestamp":1739556283,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日02时04分，Organovo Holdings, Inc.股票出现波动，股价大幅上涨5.82%。截至发稿，该股报0.400美元/股，成交量8.5386万股，换手率0.56%，振幅6.08%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.50%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150204439885bb0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150204439885bb0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","BK4139","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511243345","title":"Organovo Holdings, Inc.盘中异动 早盘快速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511243345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511243345?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:43","pubTimestamp":1739461383,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时43分，Organovo Holdings, Inc.股票出现波动，股价急速上涨5.02%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213234303abcdc059&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213234303abcdc059&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509791469","title":"MNC年报扫描｜巨头“厮杀” 国产“逐鹿”：自免领域5大单品狂揽近530亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509791469","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509791469?lang=zh_cn&edition=full","pubTime":"2025-02-07 16:39","pubTimestamp":1738917574,"startTime":"0","endTime":"0","summary":"随着跨国药企（MNC）陆续披露2024年业绩，21世纪经济报道记者初步统计发现，自免领域的营收排名中，赛诺菲的度普利尤单抗、艾伯维的利生奇珠单抗和阿达木单抗、强生的乌司奴单抗、罗氏的奥瑞利珠单抗位居前5，年内销售额合计529.31亿美元。在这5款产品中，度普利尤单抗作为全球首个获批上市的IL-4Rα靶向单抗，凭借不断拓宽的适应症，成为全球“自免新王”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502073313516026.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502073313516026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBD","BK4116","CD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inspireetf.com/etf/inspire-corporate-bond-impact-etf/","stockEarnings":[{"period":"1week","weight":0.0025},{"period":"1month","weight":-0.0109},{"period":"3month","weight":-0.0137},{"period":"6month","weight":-0.0133},{"period":"1year","weight":-0.0046},{"period":"ytd","weight":-0.0153}],"compareEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.0211},{"period":"1year","weight":0.3041},{"period":"ytd","weight":-0.0337}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.001543},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.005311},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010014},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.000009},{"month":5,"riseRate":0.75,"avgChangeRate":0.005151},{"month":6,"riseRate":0.625,"avgChangeRate":0.002487},{"month":7,"riseRate":0.75,"avgChangeRate":0.005658},{"month":8,"riseRate":0.555556,"avgChangeRate":0.001806},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.008441},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.00662},{"month":11,"riseRate":0.555556,"avgChangeRate":0.009166},{"month":12,"riseRate":0.333333,"avgChangeRate":0.000853}],"exchange":"ARCA","name":"Inspire Corporate Bond ETF","nameEN":"Inspire Corporate Bond ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inspire Corporate Bond ETF(IBD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inspire Corporate Bond ETF(IBD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inspire Corporate Bond ETF,IBD,Inspire Corporate Bond ETF股票,Inspire Corporate Bond ETF股票老虎,Inspire Corporate Bond ETF股票老虎国际,Inspire Corporate Bond ETF行情,Inspire Corporate Bond ETF股票行情,Inspire Corporate Bond ETF股价,Inspire Corporate Bond ETF股市,Inspire Corporate Bond ETF股票价格,Inspire Corporate Bond ETF股票交易,Inspire Corporate Bond ETF股票购买,Inspire Corporate Bond ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inspire Corporate Bond ETF(IBD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inspire Corporate Bond ETF(IBD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}